How much funding has DEM Bio raised?

DEM Bio has raised $70.0M in total funding, most recently a Seed round.

Who are DEM Bio's investors?

DEM Bio's investors include Longwood Fund, Alta Partners, Insight Partners, Alexandria Venture Investments, Astellas Venture Management, DC Investment.

Where is DEM Bio headquartered?

DEM Bio is headquartered in Boston, Massachusetts, United States.

What industry is DEM Bio in?

DEM Bio operates in Life Sciences.

DEM Bio

Novel Targets for Solid Tumors. First-in-Class Cancer Therapeutics.

Boston, United States · Founded 2022 · $70.0M raised

Life Sciences

Headquarters: Boston, Massachusetts
Employees: 11–50
Founded: 2022
Business Model: B2B

Website: dembiopharma.com
Total Funding: $70.0M
Last Round: $70.0M SeedJun 2022
Rounds: 1

About

DEM BioPharma is a clinical-stage biopharmaceutical company dedicated to discovering novel targets for solid tumors and developing innovative, first-in-class cancer therapeutics. The company's lead program, DEM301, is an antibody-drug conjugate (ADC) targeting a novel innate immune checkpoint pathway. DEM Bio's approach focuses on unleashing macrophages and immune phagocytes to eliminate tumors by targeting 'don't eat me' (DEM) signals — a distinct mechanism from conventional checkpoint inhibitors. Headquartered in Cambridge, Massachusetts, DEM Bio was founded in 2022 and is backed by a world-class scientific and operating team.

Summary

DEM Bio is a Life Sciences company based in Boston, United States, founded in 2022. It has raised $70.0M in total across 1 round, most recently a $70.0M Seed round in Jun 2022. Investors include Longwood Fund, Alta Partners and Insight Partners.